Key Takeaways
- A quarter hit by a storm of external shocks: Revenue fell 16% QoQ as collapsing raw material prices, geopolitical disruptions, and US tariff uncertainty converged, but management insists volumes are largely intact and a strong recovery is coming.
- Margins absorbed a triple blow: EBITDA dropped 19% QoQ to ₹215 crore, bruised by ₹30 crore in inventory valuation losses, temporary plant shutdowns from India-Pakistan tensions, and export deferments.
- The three-year ₹1,800 crore EBITDA target stands firm: Management declined to give annual guidance but reiterated confidence in the medium-term goal, pointing to cost-saving initiatives running ahead of schedule and new high-margin capacity coming online from H2.
- US tariffs are a fresh, unquantified risk: Announced the night before the call, tariffs threaten the DCB export portfolio and MMA; management is still studying the fine print and promises mitigation plans in two to three weeks.
- What to watch next quarter: Whether raw material prices have truly bottomed, the tariff mitigation strategy for DCB and MMA, and any sign that agrochemical intermediate pricing is turning.
The Quarter's Damage: What Happened and Why
- Raw material collapse drove revenue down, not volume destruction: Benzene and aniline prices fell 15–20% over the quarter, and management believes the decline has now bottomed after some stabilization and a minor uptick in the last 1.5–2 months.
- Geopolitics disrupted operations directly: India-Pakistan tensions briefly impacted the Kutch facility and caused congestion and shutdowns at Kandla Port, hitting export realizations and plant throughput in June.
- Inventory losses bit hard: A ₹30 crore inventory valuation hit flowed through EBITDA as falling input prices devalued stock, a mechanical consequence of the raw material environment.
- Export deferment compounded the pain: Global geopolitical uncertainty led customers to defer export orders, while the domestic market held up relatively well through June.
- Operational issues added a domestic drag: The nitrochlorobenzene unit and chloroaniline-related assets faced operational challenges in June, pulling down domestic volumes in a portfolio that is 99% domestic.
Suyog Kotecha: "I think I would not say it has established as a firm trend. We see, of course, stray incidences where realizations have been taken up in the last few months. But I would still hesitate to characterize it as a generic trend."
Product Chain Health: Where the Pain and Promise Sit
| Segment | Trend | Commentary |
|---|---|---|
| Energy Applications (MMA) | ▬ Flattish volumes | Demand strong but pricing under pressure from competition and falling RM; improving crack spreads expected to help; US tariff risk now added. |
| Agrochemical Intermediates | ▼ Pricing pressure | Volumes picking up but intermediates lag downstream recovery; improvement needs both demand uptick and capacity absorption, a multi-quarter story. |
| Dyes, Pigments, Pharma | ▬ Stable | No major deterioration flagged. |
| Polymers & Additives (ex-DCB) | ▲ Demand recovery | Parts of the segment showing very good demand recovery. |
| DCB | ▼ Sharp weakness | US automotive customers going through inventory liquidation and demand uncertainty; exports to US significantly lower YoY and QoQ; tariffs now add competitive pressure. |
| NCB | ▼ Volume decline | Driven by strategic customer challenges and June operational issues at the nitrochlorobenzene unit; entirely domestic. |
- DCB tariff exposure is direct and immediate: The US tariff announcement creates increased competition on the DCB portfolio exported to America; management aims to retain market share through cost competitiveness, but concedes it may come at the expense of margins.
- MMA strategy is to defend global leadership: Management claims the least-cost position globally based on internal benchmarking and has already provisioned for capacity expansion with minor capex; mitigation for US tariffs and new market development in Europe are underway.
Suyog Kotecha: "We have a market leadership position globally in this product, and we would like to continue to maintain that. And we have the least cost position as far as our internal benchmarking exercise goes with respect to competition."
The Growth Bet: Zone-IV and New Capacity
- Phase-I is near: The multipurpose plant and calcium chloride unit are at advanced stages of mechanical completion and handover, with commissioning expected by December 2025.
- The full ramp is a phased story: Five additional blocks will commission in stages from January to May next year, with the full potential of Zone-IV materializing over the next one and a half years.
- Margin ambition is explicit: Management is targeting a 20% plus EBITDA margin profile for most new products from Zone-IV and the multipurpose plant, aiming to return Aarti to the margin levels of five years ago.
- Nitrotoluene and Ethylation already scaled: Nitrotoluene capacity moved from 30 to 45 KTPA and Ethylation from 10 to 30 KTPA; both are now in ramp-up.
- MMA has headroom: Capacity scaled from 200 to roughly 260 KTPA with further expansion possible using limited capex, provisioning already done.
- Augene JV with UPL is on track: Project execution progressing well, commissioning expected in H1 CY26, market development activities already initiated.
- Recycling venture advancing: Aarti Circularity Ltd has completed technology selection; pre-processing design and capex finalization in progress, with commercial operations expected early FY27.
Suyog Kotecha: "We are talking about historical five years back if you look at what was the AIL's margin profile, we are targeting to go back to those kind of margin levels with these new products coming in. So, 20% plus EBITDA kind of margin profile for most of these products."
Cost and Capital Discipline
- Cost-saving initiatives are ahead of schedule: A new back-pressure turbine at Vapi, yield improvements, and steam consumption gains are already implemented; without them, profitability would have been significantly lower.
- 65–70% of the ₹150–200 crore program lands this year: The solar component commissions from November/December this year, the hybrid component around April/May next year; the remaining ~30% spills into next year.
- Capex is tapering sharply: FY26 capex expected below ₹1,000 crore, and next year's number will drop dramatically from that level.
- Net debt is capped: Expected to remain roughly around the ₹3,500 crore level with no material increase.
- Capital allocation is becoming selective: Management is mindful of global demand-supply balances and is optimizing the design and portfolio of ongoing projects to ensure the best returns.
Suyog Kotecha: "We are mindful of the global demand/supply balances and where should we allocate incremental capital going forward. At the same time, the projects which we have taken on, I think we are going through them while optimizing the design and the portfolio of those capex to ensure that we get best returns out of it."
China, Competition, and the Pricing Cycle
- Competitive intensity with China has not materially risen: It remains at 70–75% of the product basket competing with China; management believes pricing levels have bottomed and the game is now about efficiency to survive and gain share when the cycle turns.
- Overcapacity is structural, not cyclical: Management acknowledges significant overcapacity in China and that demand-supply balancing will not happen with just one year of demand growth. [15–16]
- Agrochemical pricing recovery is a slow burn: Intermediates see the impact later than downstream technicals and formulations; improvement needs both a demand uptick and capacity absorption, a timeframe longer than one or two quarters.
- Profitability should track volume growth from here: On an absolute basis, profitability growth should track volume growth going forward, not lag.
Suyog Kotecha: "It is fair to say we are talking about significant overcapacity and the demand/supply balancing will not happen with one year of demand growth." [15–16]
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Three-year EBITDA target | ₹1,800 crore | FY26–28 (three-year horizon) |
| Zone-IV Phase-I commissioning | Multipurpose plant and calcium chloride unit | December 2025 |
| Zone-IV remaining blocks | Five additional blocks, phased commissioning | January to May 2026 |
| Augene JV commissioning | Project completion and start-up | H1 CY26 |
| Aarti Circularity operations | Commercial operations begin | Early FY27 |
| FY26 capex ceiling | Below ₹1,000 crore | FY26 |
| Next year capex drop | Dramatic reduction from ~₹1,000 crore | FY27 |
| Net debt ceiling | Remain roughly around ₹3,500 crore | Ongoing |
| Cost-saving program | 65–70% of ₹150–200 crore implemented | Within FY26 |
| Solar cost initiative commissioning | Solar component online | November/December 2025 |
| Hybrid cost initiative commissioning | Hybrid component online | April/May 2026 |
| DCB volume recovery | Second-half recovery as customer inventory correction ends | H2 FY26 |
| US tariff mitigation plan | Clarity on MMA and DCB mitigation actions | Two to three weeks |
| New product margin profile | 20% plus EBITDA margin for most Zone-IV/MPP products | As new capacity commercializes |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue | ₹1,867 cr, decline of 16% QoQ |
| EBITDA | ₹215 cr, decline of 19% QoQ |
| Profit After Tax | ₹43 cr |
| Exports | ₹950 cr |
| Capex | ₹280 cr; FY26 expected below ₹1,000 cr |
| Net debt | ~₹3,500 cr (peak level); reduction of ₹200–300 cr targeted in FY26 |
| Inventory valuation loss | ₹30 cr |
| EBITDA impact from delayed shipments | ₹15–20 cr |
| Foreign exchange gain | ₹16 cr |
| MMA capacity | ~260 KTPA, scaled up from 200 KTPA |
| Nitrotoluene capacity | 45 KTPA, scaled up from 30 KTPA |
| Ethylation capacity | 30 KTPA, scaled up from 10 KTPA |
| US revenue exposure | 15–20% of revenues (direct exports) |
| July MMA exports | ~20,000–22,000 tons |